Heart failure drug study halted early after only 4 patients
NCT ID NCT06581159
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This early-stage study tested a new drug called HS135 in obese people with both heart failure (with preserved pumping ability) and high blood pressure in the lungs. The trial was stopped early after enrolling only 4 participants, so no conclusions can be drawn about safety or effectiveness. The main goal was to check for side effects and measure changes in blood tests and heart pressures over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site-104
Phoenix, Arizona, 85016, United States
-
Site-105
Kansas City, Missouri, 64111, United States
Conditions
Explore the condition pages connected to this study.